The drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had tumors removed in surgery.
FILE - A sign marks an entrance to a Moderna building in Cambridge, Mass., on Monday, May 18, 2020. Shares of Merck and Moderna jumped early Tuesday, Dec. 13, 2022, after the drugmakers said a potential skin cancer vaccine they are developing using the same technology behind COVID-19 preventive shots did well in a mid-stage study.
The drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in survival before the cancer returned in patients with advanced melanoma. Moderna developed one of the most popular vaccines used to protect patients against COVID-19, and the drugmaker brought in more than $3 billion from its Spikevax in this year's third quarter.Like Spikevax, the potential skin cancer vaccine uses mRNA technology. It trains a patient’s immune system to recognize and respond specifically to mutations in the DNA of the patient’s tumor.
The patient group that took the potential vaccine and Keytruda saw a 44% reduction in the risk of death or the cancer returning, the companies said.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Merck, Moderna detail potential skin cancer vaccine progressMerck and Moderna said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had the tumors removed in surgery.
Leer más »
Moderna and Merck team-up to fight melanomaVaccine-maker Moderna has partnered with the biopharmaceutical company Merck to create an effective treatment for skin cancer
Leer más »
Merck, Moderna detail potential skin cancer vaccine progressThe drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had tumors removed in surgery.
Leer más »
Merck, Moderna share positive progress of potential skin cancer vaccineA potential skin cancer vaccine being developed using the same technology behind COVID shots fared well in a small study, the drug companies said. FOX13
Leer más »
Positive Moderna, Merck cancer vaccine data advances mRNA promise, shares riseAn experimental cancer vaccine from Moderna based on the messenger RNA technology used in successful COVID vaccines has been shown to work against melanoma.
Leer más »
Merck, Moderna detail potential skin cancer vaccine progressThe drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had tumors removed in surgery.
Leer más »